Celsion announces enrollment of first patient in global phase III OPTIMA study
Celsion announced the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation in patients with primary liver cancer. ThermoDox® is Celsion's proprietary, heat-activated, liposomal encapsulation of doxorubicin. September 02, 2014